芬兰65岁及以上人群二价加强针对重症COVID-19结局的相对有效性,2022年9月至2023年8月
基于芬兰登记数据的队列分析纳入1,191,871名65岁及以上人群,比较接种二价加强针与未接种者重症COVID-19结局风险。2022年9月至2023年2月接种后14-60天,住院风险比为0.45(95%CI:0.37-0.55),死亡风险比为0.49(95%CI:0.38-0.62)。2023年3月至8月接种后61-120天住院风险比为0.53(95%CI:0.39-0.71),此后未见明显风险降低。
要点
- 2022年9月至2023年2月,二价加强针接种后14-60天与COVID-19住院风险降低相关(HR:0.45;95%CI:0.37-0.55)。
- 2023年3月至8月,接种后61-120天住院风险比为0.53(95%CI:0.39-0.71),此后未见明显风险降低。
- 原始/Omicron BA.1与原始/BA.4-5加强针之间未发现差异。
核心结论
- 二价加强针最初使65岁及以上人群重症COVID-19结局风险降低约50%,但保护力随时间减弱。
研究设计与样本
- 基于登记数据的队列分析,纳入1,191,871名65岁及以上人群,比较接种二价加强针(暴露组)与未接种者(未暴露组)在2022年9月1日至2023年8月31日期间三种重症COVID-19结局的风险。
- 纳入标准为2022年9月1日前至少接种两剂单价COVID-19疫苗且最后一剂接种已满3个月。
- 分析分为两个时期:2022年9月1日至2023年2月28日(BA.5和BQ.1.X优势)和2023年3月1日至2023年8月31日(XBB优势)。
- 采用Cox回归比较暴露组与未暴露组结局的风险比。
主要发现
- 2022年9月1日至2023年2月28日,二价加强针接种后14-60天与COVID-19住院风险降低相关(HR:0.45;95%CI:0.37-0.55)。
- 2022年9月1日至2023年2月28日,二价加强针接种后14-60天与COVID-19死亡风险降低相关(HR:0.49;95%CI:0.38-0.62)。
- 2022年9月1日至2023年2月28日,二价加强针接种后14-60天与COVID-19作为促死因素的死亡风险降低相关(HR:0.40;95%CI:0.31-0.51)。
- 2023年3月1日至2023年8月31日,二价加强针接种后61-120天与所有三种重症COVID-19结局风险降低相关(例如COVID-19住院HR:0.53;95%CI:0.39-0.71),此后未见明显风险降低。
- 原始/Omicron BA.1与原始/BA.4-5加强针之间未发现差异。
临床怎么用
- 作者认为这些发现有助于指导疫苗开发和疫苗接种规划。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundLong-term effectiveness data on bivalent COVID-19 boosters are limited.AimWe evaluated the long-term protection of bivalent boosters against severe COVID-19 among ≥ 65-year-olds in Finland.MethodsIn this register-based cohort analysis, we compared the risk of three severe COVID-19 outcomes among ≥ 65-year-olds who received a bivalent booster (Original/Omicron BA.1 or Original/BA.4-5; exposed group) between 1/9/2022 and 31/8/2023 to those who did not (unexposed). We included individuals vaccinated with at least two monovalent COVID-19 vaccine doses before 1/9/2022 and ≥ 3 months ago. The analysis was divided into two periods: 1/9/2022-28/2/2023 (BA.5 and BQ.1.X predominating) and 1/3/2023-31/8/2023 (XBB predominating). The hazards for the outcomes between exposed and unexposed individuals were compared with Cox regression.ResultsWe included 1,191,871 individuals. From 1/9/2022 to 28/2/2023, bivalent boosters were associated with a reduced risk of hospitalisation due to COVID-19 (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.37-0.55), death due to COVID-19 (HR: 0.49; 95% CI: 0.38-0.62), and death in which COVID-19 was a contributing factor (HR: 0.40; 95% CI: 0.31-0.51) during 14-60 days since vaccination. From 1/3/2023 to 31/8/2023, bivalent boosters were associated with lower risks of all three severe COVID-19 outcomes during 61-120 days since a bivalent booster (e.g. HR: 0.53; 95% CI: 0.39-0.71 for hospitalisation due to COVID-19); thereafter no notable risk reduction was observed. No difference was found between Original/Omicron BA.1 and Original/BA.4-5 boosters.ConclusionBivalent boosters initially reduced the risk of severe COVID-19 outcomes by ca 50% among ≥ 65-year-olds, but protection waned over time. These findings help guide vaccine development and vaccination programmes.
引用
- Poukka E, Perälä J, Nohynek H, et al. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023. Euro Surveill. 2024. PMID: 39268649. doi:10.2807/1560-7917.ES.2024.29.37.2300587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。